178 related articles for article (PubMed ID: 3539901)
1. Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.
Tomatsu K; Ando S; Masuyoshi S; Hirano M; Miyaki T; Kawaguchi H
J Antibiot (Tokyo); 1986 Nov; 39(11):1584-91. PubMed ID: 3539901
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
Kessler RE; Bies M; Buck RE; Chisholm DR; Pursiano TA; Tsai YH; Misiek M; Price KE; Leitner F
Antimicrob Agents Chemother; 1985 Feb; 27(2):207-16. PubMed ID: 3885849
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
Fuchs PC; Jones RN; Barry AL; Thornsberry C
Antimicrob Agents Chemother; 1985 May; 27(5):679-82. PubMed ID: 3893316
[TBL] [Abstract][Full Text] [Related]
5. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
Neu HC; Chin NX; Jules K; Labthavikul P
J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
[TBL] [Abstract][Full Text] [Related]
6. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
Vuye A; Pijck J
Antimicrob Agents Chemother; 1985 Apr; 27(4):574-7. PubMed ID: 3859244
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin.
Une T; Otani T; Sato M; Ikeuchi T; Osada Y; Ogawa H; Sato K; Mitsuhashi S
Antimicrob Agents Chemother; 1985 Apr; 27(4):473-8. PubMed ID: 3873898
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
Tsuji A; Maniatis A; Bertram MA; Young LS
Antimicrob Agents Chemother; 1985 Apr; 27(4):515-9. PubMed ID: 3839120
[TBL] [Abstract][Full Text] [Related]
9. Biological activity of BO-1236, a new antipseudomonal cephalosporin.
Nakagawa S; Sanada M; Matsuda K; Hazumi N; Tanaka N
Antimicrob Agents Chemother; 1987 Jul; 31(7):1100-5. PubMed ID: 3116919
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
Giamarellou H; Sahin A; Chryssouli Z
Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.
Hebeisen P; Heinze-Krauss I; Angehrn P; Hohl P; Page MG; Then RL
Antimicrob Agents Chemother; 2001 Mar; 45(3):825-36. PubMed ID: 11181368
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluations of a new broad-spectrum oral cephalosporin, BMY-28232, and its prodrug esters.
Tomatsu K; Masuyoshi S; Hirano M; Kawaguchi H; Oki T; Fung-Tomc J; Desiderio JV; Kessler RE
Antimicrob Agents Chemother; 1989 Apr; 33(4):489-97. PubMed ID: 2786371
[TBL] [Abstract][Full Text] [Related]
15. Cefepime: overview of activity in vitro and in vivo.
Grassi GG; Grassi C
J Antimicrob Chemother; 1993 Nov; 32 Suppl B():87-94. PubMed ID: 8150771
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.
Fuchs PC; Jones RN; Barry AL; Ayers LW; Gavan TL; Gerlach EH
Diagn Microbiol Infect Dis; 1986 Nov; 5(4):345-9. PubMed ID: 3536278
[TBL] [Abstract][Full Text] [Related]
17. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Chapman TM; Perry CM
Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
[TBL] [Abstract][Full Text] [Related]
18. The in-vitro activity of ceftazidime against clinically important pathogens.
Knothe H; Dette GA
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():33-41. PubMed ID: 19810167
[TBL] [Abstract][Full Text] [Related]
19. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
